Share Name Share Symbol Market Type Share ISIN Share Description
Okyo Pharma LI. LSE:OKYO London Ordinary Share GG00BD3FV870 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -10.00% 2.25p 2.00p 2.50p 2.50p 2.05p 2.50p 1,707,262 14:29:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Mining 0.0 -0.5 -0.1 - 8.74

Okyo Pharma LI. Share Discussion Threads

Showing 201 to 223 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
18/8/2018
17:58
The scumbags like Reks, Shirley, letmepass need locking up.
bennie_m
17/8/2018
14:11
6p high + to 2p..of course the usual suspects do not care, they just move onto the next pump and dump dave454520 Jul '18 - 08:50 - 53 of 208 Edit 0 1 0 Jeez they never take a day off do they. Just leave a trail of destruction.
dave4545
17/8/2018
14:04
Where's that scammer Reks? Hope you all contact the Police, they can seize his bedsit to pay for his criminal activity
bennie_m
16/8/2018
12:56
Cash is burning. One day there will be no cash left. That is the reality.
kingston78
15/8/2018
19:42
1.2m cash and mcap is still 9.7m. Cash could be closer to £1m. Come back when share price is 0.2p
booyakasha
14/8/2018
11:27
Some people pumped up these shares and the price is gradually crashing down to earth. The company will have to raise new funds to keep it going. This is a concept company without substance.
kingston78
03/8/2018
12:36
whoooosh ......all the way down to 1p.this dog should have never been resurrected from the ashes of wafm
kasspass
02/8/2018
12:25
The company needs to pay for overheads. It has no income. That's why the money pot gets smaller day by day.
kingston78
01/8/2018
17:48
Lower highs and lower lows dejavu
stenick
01/8/2018
16:21
Again read the prospectus you will get your answers, first they had no money now you’vre realised they have near 2M, next you feel this is just going to vanish! Really - what’s next?
zen12
01/8/2018
16:16
The company had £2 million as at 31/3/2018. The amount that it has now would be less after paying overheads. It is about time that they will do a placing, maybe at 2 p each.
kingston78
01/8/2018
15:28
OK I may gamble £500 at 0.5p.
cool druid
01/8/2018
14:36
Well can’t do work for you, if you want to invest then you’re gonna have to start doing some research! Rather than throw snippets in the dark.
zen12
01/8/2018
14:29
what's the potential? remind us.
cool druid
01/8/2018
14:09
What you’re forgetting is market doesn’t value a company just on cash but also it’s potential. It looks like you guys taking turns to bash the company on a nothing rns! Long holders know all of this from previous rns’s and company prospectus so nothing new in rns to excite either.
zen12
01/8/2018
13:46
large investor with significant holding, and? and they are a big of worthless garbage. what's the quivalent of £2m in terms of sp? is it about 0.5p?
cool druid
01/8/2018
13:41
See rns they have £2m in the bank. Also large investors with significant holdings. So what you’re saying is totally incorrect.
zen12
01/8/2018
13:28
Many companies such as OKYO have little or no money, and yet they are in the business of investing. Ambitions get the better of the directors. OKYO will have to raise capital soon in order to survive, let alone investing. Quite often, directors use investors' money to pay for their salaries, travel and entertaining expenses. Many of them live a good life at the expense of shareholders.
kingston78
01/8/2018
13:17
pasting part of the rns, as to reflect a bit of reality after reading lots of ramping posts here and the LSE site.....saves some investors getting into a ramp
euclid5
01/8/2018
07:46
RNS - Reads very much like their prospectus a few weeks ago. This extract is interesting though as it appears their off the ground with the Chemerin project: Since the first quarter of 2018, the Company had been engaged in re-listing activity which was became effective on 17 July 2018. At the same time, the Company remained focused on setting up life science operations in order to seek to develop the Chemerin Project.’
zen12
31/7/2018
21:06
Why do people have to copy the RNSPerhaps they think people are stupid and will not see it ?
bckttsim
31/7/2018
20:49
"Early stage of operations The Company's operations are at an early stage of development and there can be no guarantee that the Company will be able to, or that it will be commercially advantageous for the Company to, develop its proprietary technology and acquire scientific assets. Further, the Company has no positive operating cash flow and its ultimate success will depend on the Board's' ability to implement the Company's strategy, generate cash flow and access equity markets. Whilst the Board is optimistic about the Company's prospects, there is no certainty that anticipated outcomes and sustainable revenue streams will be achieved. The Company will not generate any material income until commercialisation or licensing of its scientific assets has successfully commenced and in the meantime the Company will continue to expend its cash reserves. There can be no assurance that the Company's proposed operations will be profitable or produce a reasonable return, if any, on investment" Technology and products The Company is a drug discovery and development Company. The development and commercialisation of its scientific assets, will require research progress and positive results from multiple clinical trials, which by their very nature are inherently uncertain. There is a risk that safety issues may arise when the products are tested. This risk is common to all new classes of drugs and, as with all other drug companies, there is a risk that trials may not be successful. The Board takes steps to ensure that all research partners adhere to industry standard guidelines. Research and development risk The Company operates in the life sciences and biopharmaceutical development sector and will be looking to exploit opportunities within that sector. The Company is therefore involved in complex scientific research, and industry experience indicates that there may be a very high incidence of delay or failure to produce results. The Company may not be able to develop new products or to identify specific market needs that can be addressed by technology solutions developed by the Company. The ability of the Company to develop new technology relies, in part, on the recruitment of appropriately qualified staff as the Company grows, or to identify and collaborate with high quality scientific teams and investigators. The Company may be unable to find a sufficient number of appropriately highly trained individuals to satisfy its growth rate which could affect its ability to develop as planned. Product development timelines Product development timelines are at risk of delay, particularly since it is not always possible to predict the rate of patient recruitment into clinical trials. There is a risk therefore that product development could take longer than presently expected; if such delays occur the Company may require further working capital. The Company will seek to minimise the risk of delays by careful management of projects. Uncertainty related to regulatory approvals The Company will need to obtain various regulatory approvals and otherwise comply with extensive regulations regarding safety, quality and efficacy standards in order to market its future products. These regulations, including the time required for regulatory review, vary from country to country and can be lengthy, expensive and uncertain. While efforts will be made to ensure compliance with government standards, there is no guarantee that any products will be able to achieve the necessary regulatory approvals to promote that product in any of the targeted markets and any such regulatory approval may include significant restrictions for which the Company's products can be used. In addition, the Company may be required to incur significant costs in obtaining or maintaining its regulatory approvals. Delays or failure in obtaining regulatory approval for products would be likely to have a serious adverse effect on the value of the Company and have a consequent impact on its financial performance and ability to continue as a going concern without raising additional finance. The Board takes steps to mitigate this risk by the appointment of regulatory specialists prior to any regulatory applications. Future funding requirements The Company will need to raise additional funding in the future to undertake work beyond that being funded by the Company's current cash reserves. There is no certainty that this will be possible at all or on acceptable terms. In addition, the terms of any such financing may be dilutive to, or otherwise adversely affect, existing shareholders. Https://www.investegate.co.uk/okyo-pharma-limited--okyo-/rns/final-results/201807311805093880W/
euclid5
31/7/2018
12:34
Looks like news incoming regarding licenses
reks
Chat Pages: 9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180819 06:00:47